3.1. Study Design
This randomized controlled clinical trial was conducted at cancer centers affiliated with Rafsanjan University of Medical Sciences, located in Rafsanjan, Kerman province, Iran, from December 2022 to May 2023.
Upon approval of the research project, sampling commenced. One of the researchers, a nurse, visited the cancer centers, explained the study's objectives, and obtained informed written consent from eligible participants.
3.2. Study Participants and Sampling
Participants included family members of cancer patients admitted to cancer centers affiliated with Rafsanjan University of Medical Sciences within six months of their cancer diagnosis. Initially, purposeful sampling was conducted based on predefined inclusion criteria. Subsequently, eligible participants were assigned to two study groups (A: Education based on family members' needs, B: Structured education) using the random minimization method. This allocation was based on educational background (diploma or academia) and baseline anxiety intensity categories (moderate or severe). Randomization units were sequentially enrolled, with the first sample in each category and study group determined by random drawing using sealed envelopes. Subsequent samples with matching characteristics were assigned to the remaining group within the same category. This process continued until the desired sample size was reached.
3.3. Inclusion Criteria
Participants had to be above 18 years old, first-degree family members of the patient (spouse, father, mother, child, siblings), possess at least a high school diploma, demonstrate sufficient cognitive ability to learn, comprehend, and communicate, not have a known psychopathy or substance abuse history, not have experienced adverse events in the past six months, receive a cancer diagnosis within the last six months, and obtain a moderate to high anxiety score on the Spielberger State Anxiety Inventory.
3.4. Exclusion Criteria
Exclusion criteria included reluctance to participate in the study and the occurrence of any acute conditions.
The sample size was calculated to be 80 family members of cancer patients, with 40 participants in each group. This calculation was based on the following formula, with a standard deviation of 4.5, significance level of 0.05, power of 90%, and an effect size of 3.3 in terms of the minimum difference in means changes between groups (
19):
3.5. Intervention
After allocating samples to groups, family members in group A received cancer-related health information tailored to their needs and questions. For group B, information was provided in a structured format based on a pre-prepared protocol in a booklet. This information covered various topics such as the nature of cancer, diagnostic and treatment methods, disease progression and consequences, treatment complications, symptoms of disease recurrence, acceptance of the disease by the patient and family, recognition of symptoms requiring immediate intervention, psychological changes in response to cancer, emotional support, proper patient interaction, nutrition, home rehabilitation, and resumption of normal activities.
Since family members had varying information needs, the content provided in group A was individualized based on their questions, with the amount and type of information determined by the nurse researcher in response to these questions. The intervention period for group A ended when all family members' questions were addressed, while for group B, it concluded when all the information outlined in the booklet was provided.
3.6. Data Collection Tool and Technique
The data collection tool consisted of two parts: The first part was demographic information, and the second part was the Spielberger State Anxiety Inventory. Demographic characteristics questionnaire of family members included: Age, sex, marital status, education, and family relationship.
The Spielberger State-Trait Anxiety Inventory (STAI) scale includes 20 items that measure a person's feelings at the time of answering, on a 5-point Likert scale (never score 1, rarely score 2, sometimes score 3, most of the time score 4, almost always score 5). The validity of the scale has been reported with a Cronbach's alpha coefficient of 0.92 and a reliability coefficient of 0.73 to 0.86. The Spielberger's standard questionnaire was standardized on 600 subjects in Mashhad in Mahram's research in 2012. The reliability of the test has been calculated as 0.9451 through Cronbach's alpha formula. Also, for the criteria group separately, this reliability has been calculated and its value is reported as 0.9418. The standard error of the test measurement was calculated as 4.643. Additionally, the correlation of the observed scores with the true score equals 0.972 and with the error scores was calculated to be equal to 0.234 (
20).
Measurements were performed at two times. The first measurement was before entering the study as a baseline, and the second measurement was after completing the intervention. Data collection was conducted by the researcher's colleague who was blind to the allocation of samples in the study groups, through face-to-face interviews.
3.7. Statistical Analysis
Data were analyzed using SPSS software version 22, by Shapiro and Wilk statistical tests (to check the normality of quantitative data distribution), chi-square and Fisher's exact test (to compare proportions), Paired Samples T-test (to compare within groups), and independent t-test (for comparison between groups) at a significance level of 0.05.
3.8. Ethical Considerations
In this study, ethical issues in research such as the approval of a research project in the ethics committee in biomedical research (with the code IR.RUMS.REC.1401.092) and obtaining the IRCT code from the Iranian Clinical Trials (IRCT20230611058452N1), obtaining informed consent, freedom to leave the study, confidentiality, and assurance to the participants that their participation or non-participation in the study did not change the quality of patient care, were considered.